Φορτώνει......
A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug
BACKGROUND AND PURPOSE: ATB‐346 is a hydrogen sulfide (H(2)S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Br J Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7024706/ https://ncbi.nlm.nih.gov/pubmed/30834513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14641 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|